Stay updated with breaking news from Palatin Technologies. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Investors might want to bet on Palatin Technologies, Inc. (AMEX:PTN), as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.
HC Wainwright reissued their buy rating on shares of Palatin Technologies (NYSEAMERICAN:PTN – Free Report) in a research note published on Wednesday, Benzinga reports. The brokerage currently has a $17.00 price target on the biopharmaceutical company’s stock. Palatin Technologies Stock Down 2.0 % Palatin Technologies stock opened at $2.00 on Wednesday. Palatin Technologies has a […]
Palatin Technologies, Inc. (PTN) announced the FDA has completed 30-day review of the investigational new drug application for the use of bremelanotide, a melanocortin receptor 4 agonist, for the treatment of obesity.
/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that...
Shares of Palatin Technologies, Inc. (NYSEAMERICAN:PTN – Get Free Report) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.00 and traded as high as $2.17. Palatin Technologies shares last traded at $2.08, with a volume of 816,735 shares. Analyst Ratings Changes Separately, HC Wainwright […]